Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Convergent action on AMR identified as an important area of intervention
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Urges Innovators to produce quality products that can be deployed at scale
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Subscribe To Our Newsletter & Stay Updated
